21 years of historical data (2004–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Genfit S.A. trades at 256.9x earnings, 301% above its 5-year average of 64.0x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 1061%. On a free-cash-flow basis, the stock trades at 27.1x P/FCF, 240% above the 5-year average of 8.0x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $448M | $187M | $191M | $218M | $278M | $187M | $736M | — | — | — | — |
| Enterprise Value | $425M | $167M | $184M | $157M | $94M | $201M | $643M | — | — | — | — |
| P/E Ratio → | 256.88 | 124.00 | — | — | 4.07 | — | — | — | — | — | — |
| P/S Ratio | 5.75 | 2.79 | 6.70 | 10.80 | 3.47 | 243.82 | 23.87 | — | — | — | — |
| P/B Ratio | 5.59 | 2.70 | 2.82 | 2.31 | 2.33 | — | 8.76 | — | — | — | — |
| P/FCF | 27.10 | 13.14 | — | — | 2.80 | — | — | — | — | — | — |
| P/OCF | 25.35 | 12.29 | — | — | 2.78 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Genfit S.A.'s enterprise value stands at 73.1x EBITDA, 305% above its 5-year average of 18.1x. The Healthcare sector median is 14.2x, placing the stock at a 414% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.50 | 6.43 | 7.79 | 1.17 | 262.98 | 20.85 | — | — | — | — |
| EV / EBITDA | 73.07 | 33.41 | — | — | 2.71 | — | — | — | — | — | — |
| EV / EBIT | 111.46 | 25.25 | — | — | 2.91 | — | — | — | — | — | — |
| EV / FCF | — | 11.76 | — | — | 0.94 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Genfit S.A. earns an operating margin of 4.9%. Operating margins have expanded from -135.1% to 4.9% over the past 3 years, signaling improving operational efficiency. ROE of 2.2% is modest. ROIC of 4.5% represents below-average returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.6% | 99.6% | 98.8% | 98.8% | 99.8% | 73.6% | 99.4% | -2587.0% | -1789.0% | -598.9% | -266.4% |
| Operating Margin | 4.9% | 4.9% | -93.1% | -135.1% | 39.7% | -10836.2% | -187.5% | -100701.4% | -48046.6% | -12027.5% | -3354.1% |
| Net Profit Margin | 2.2% | 2.2% | -101.2% | -117.5% | 84.0% | -13231.5% | -211.2% | -115247.8% | -49664.4% | -11854.6% | -3251.4% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.2% | 2.2% | -35.6% | -22.2% | 130.7% | -298.1% | -124.1% | -127.1% | -47.4% | -34.0% | -27.2% |
| ROA | 0.9% | 0.9% | -14.8% | -9.5% | 28.0% | -39.8% | -24.2% | -30.4% | -25.5% | -28.6% | -22.0% |
| ROIC | 4.5% | 4.5% | -42.4% | -60.5% | — | — | — | — | — | — | -1305.9% |
| ROCE | 3.1% | 3.1% | -17.1% | -13.8% | 16.5% | -38.2% | -25.3% | -30.5% | -27.3% | -32.6% | -25.9% |
Solvency and debt-coverage ratios — lower is generally safer
Genfit S.A. carries a Debt/EBITDA ratio of 12.4x, which is highly leveraged (285% above the sector average of 3.2x). The company holds a net cash position — cash of $82M exceeds total debt of $62M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 1.4x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.90 | 0.90 | 1.03 | 0.80 | 0.62 | — | 2.18 | 8.10 | 1.57 | 0.04 | 0.10 |
| Debt / EBITDA | 12.41 | 12.41 | — | — | 2.15 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -0.11 | -0.64 | -1.55 | — | -1.11 | -1.80 | -1.06 | -1.02 | -0.98 |
| Net Debt / EBITDA | -3.93 | -3.93 | — | — | -5.34 | — | — | — | — | — | — |
| Debt / FCF | — | -1.38 | — | — | -1.86 | — | — | — | — | — | — |
| Interest Coverage | 1.38 | 1.38 | -5.14 | -6.27 | 6.49 | -6.50 | -4.74 | -6.33 | -24.31 | -277.71 | — |
Net cash position: cash ($82M) exceeds total debt ($62M)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.23x means Genfit S.A. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 4.02x to 1.23x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.23 | 2.94 | 4.02 | 4.27 | 5.95 | 6.68 | 5.56 | 10.46 | 9.22 | 7.75 |
| Quick Ratio | 1.23 | 1.23 | 2.94 | 4.02 | 4.27 | 5.95 | 6.68 | 5.56 | 10.46 | 9.22 | 7.75 |
| Cash Ratio | 1.09 | 1.09 | 2.02 | 3.57 | 4.12 | 5.51 | 6.36 | 5.28 | 10.10 | 8.67 | 6.98 |
| Asset Turnover | — | 0.44 | 0.16 | 0.09 | 0.28 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.01 |
| Inventory Turnover | 75.00 | 75.00 | 85.25 | 62.00 | 40.25 | 50.50 | 44.25 | 463.50 | 557.25 | 141.79 | 68.96 |
| Days Sales Outstanding | — | 41.21 | 417.93 | 287.48 | 32.99 | 5686.84 | 142.43 | 2089.49 | 1289.87 | 10788.06 | 4160.45 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Genfit S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.4% | 0.8% | — | — | 24.6% | — | — | — | — | — | — |
| FCF Yield | 3.7% | 7.6% | — | — | 35.7% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $50M | $50M | $50M | $56M | $39M | $37M | $31M | $31M | $27M | $25M |
Compare GNFT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $448M | 256.9 | 73.1 | 27.1 | 99.6% | 4.9% | 2.2% | 4.5% | 12.4 | |
| $12B | -39.9 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — | |
| $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — | |
| $8B | 26.9 | 11.3 | 12.7 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 | |
| $3B | -25.1 | — | — | — | — | -27.0% | -32.8% | — | |
| $124M | -3.7 | — | — | — | — | -58.7% | -245.8% | — | |
| $4B | -7.1 | — | — | 86.0% | -6714.8% | -40.2% | -37.8% | — | |
| $12B | -6721.3 | 95.6 | 73.6 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 | |
| $38B | 122.9 | 67.9 | 82.1 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 | |
| $4B | -10.1 | — | — | — | — | -47.3% | -44.4% | — | |
| $1.0T | 48.1 | 34.5 | 116.2 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GNFT stock.
Genfit S.A.'s current P/E ratio is 256.9x. The historical average is 64.0x. This places it at the 100th percentile of its historical range.
Genfit S.A.'s current EV/EBITDA is 73.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 18.1x.
Genfit S.A.'s return on equity (ROE) is 2.2%. The historical average is -52.4%.
Based on historical data, Genfit S.A. is trading at a P/E of 256.9x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Genfit S.A. has 99.6% gross margin and 4.9% operating margin.
Genfit S.A.'s Debt/EBITDA ratio is 12.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.